key: cord-0853585-ao7amk72
authors: Ferré, Valentine Marie; Lebourgeois, Samuel; Menidjel, Reyene; Collin, Gilles; Chenane, Houssem Redha; Guindi, Manuella Onambele; Yazdanpanah, Yazdan; Timsit, Jean-François; Charpentier, Charlotte; Descamps, Diane; Fidouh, Nadhira; Visseaux, Benoit
title: Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
date: 2021-09-29
journal: J Infect
DOI: 10.1016/j.jinf.2021.09.017
sha: 288609ba0c44ccce6589424351b7689be9e14ce5
doc_id: 853585
cord_uid: ao7amk72

nan

To help routine antibody response follow-up, we evaluated the global concordance between anti-S IgG measurement, pseudoneutralization assay and live virus neutralization assay. The comparison between pseudo-neutralizing antibodies titers and anti-S titers was conducted on the 138 samples from vaccinated HCWs, 48 additional samples from COVID-19 patients and 16 pre-epidemic samples. We observed an overall agreement of 96% among vaccinated HCWs (n=133/138) and 100% among COVID-19 patients (n=48/48) and pre-pandemic samples (n=16/16) associated to a strong correlation between anti-S IgG and pseudo-neutralization titers with a Spearman coefficient Rho = 0.95 (p<0.0001) (Fig. 2) . Regarding the 5 non concordant results in the HCWs group, all were anti-S IgG positive but negative for pseudoneutralization. They all were obtained less than 7 days after the first vaccine dose, compatible with an early low-RBD affinity antibody production. Interestingly, CPE neutralization assay demonstrated a strong neutralizing activity of vaccinated HCWs one month after the first vaccine dose against all variants (median IQR x4) despite relatively low anti-S (median IQR) and pseudoneutralization titers (median IQR) (Fig. 2) . After the second vaccine dose, the neutralization titers were correlated with anti-S and pseudoneutralization titers (p<0.0001 for all lineages with rho's Spearman correlation test at 0.90, 0.86, 0.77 and 0.89 for B, Alpha, Beta and Gamma lineages respectively).

In the current study on BNT162b2 vaccine among HCWs, a strong antibody response was observed two months after the first vaccine dose (i.e. one month after the second dose), decreasing drastically afterwards from two months up to four months after the first dose. From four to five months after the first dose, the antibody titers kept to slightly decrease while still presenting detectable anti-S IgG and pseudoneutralization positive results. If live-virus neutralization assays demonstrated the same kinetic, its results were more concerning as 0/9, 5/9, 6/9 and 2/9 HCWs presented no or low neutralization activities (i.e. with an effective dilution below 1:50) for the historical B, Alpha, Beta and Gamma strains, respectively.

These findings are of importance as another recent study on vaccinated HCWs in Israel demonstrated that reinfections were associated with lower antibody neutralizing titers and that lower neutralizing titers were also associated with higher viral load during infection that could lead to higher risk of transmission 5 . Thus, the decrease in antibody and seroneutralization responses observed in the current work highlights the needs for additional vaccine doses evaluation. This is of peculiar importance for HCWs population which is at risk of transmission to fragile patients. 

The authors have no relevant competing interest to disclose in relation to this work.

Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG

Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

We wish to thank Florence Guimbi, Justine Riaboff and Nabil Benmalek for their participation to the current study, as well as all the staff of the virology department for their work on COVID-19, both for patients' care and research support.